




RealRate

PHARMACEUTICAL 2018

Biomarin Pharmaceutical INC
Rank 146 of 332

B:OMARIN®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 42% points. The greatest weakness of Biomarin Pharmaceutical INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 293%, being 41% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	2,207,144
Cost of Goods Sold	241,786
Intangible Assets	714,549
Liabilities, Current	816,518
Liabilities, Non-Current	59,105
Other Assets	814,732
Other Compr. Net Income	-35,777
Other Expenses	45,345
Other Liabilities	948,839
Other Net Income	21,532
Other Revenues	1,313,646
Property and Equipment	896,700
Research and Development	610,753
Selling, General and Administrative Expense	554,336

Output Variable	Value in 1000 USD
Assets	4,633,125
Liabilities	1,824,462
Expenses	1,452,220
Revenues	1,313,646
Stockholders Equity	2,808,663
Net Income	-117,042
Comprehensive Net Income	-134,930
BaseVar	4,640,381
ECR before LimitedLiability	185%
Economic Capital Ratio	293%